| SABS Stock | | | USD 3.03 0.10 3.19% |
COO
Christoph MBA is Executive COO of SAB Biotherapeutics
| Age | 53 |
| Address | 777 W 41st St., Miami Beach, FL, United States, 33140 |
| Phone | 605 679 6980 |
| Web | https://www.sabbiotherapeutics.com |
SAB Biotherapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.7473) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.53 in 2024.
Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, SAB Biotherapeutics'
Non Current Assets Total are comparatively stable compared to the past year.
Other Current Assets is likely to gain to about 2.7
M in 2024, whereas
Total Assets are likely to drop slightly above 63.5
M in 2024.
SAB Biotherapeutics currently holds 5.91
M in liabilities with Debt to Equity
(D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. SAB Biotherapeutics has a current ratio of 1.69, which is within standard range for the sector. Note, when we think about SAB Biotherapeutics' use of debt, we should always consider it together with its cash and equity.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. SAB Biotherapeutics (SABS) is traded on NASDAQ Exchange in USA. It is located in 777 W 41st St., Miami Beach, FL, United States, 33140 and employs 57 people. SAB Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
SAB Biotherapeutics Leadership Team
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Ex CFO | |
| MD MBA, Executive Officer | |
| Mark Conley, Interim Officer | |
| Eddie Sullivan, President, CoFounder | |
| Carlos Carillo, Senior Affairs | |
| Christoph MBA, Executive COO | |
| Michael King, EVP CFO | |
| Samuel Reich, Executive Chairman | |
| Christine MBA, CoFounder Director | |
| Edward DVM, CoFounder Observer | |
SAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SAB Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to
measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to
predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.